Résumé
Abstract Objective To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods A twelve-week prospective open-label cohort study to compare four subgroups according to first-episode schizophrenia patients' type of drug usage and sex: female aripiprazole (n = 11), male aripiprazole (n = 11), female olanzapine (n = 10), and male olanzapine (n = 11) for body mass index, fasting serum triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and fasting glucose. Results Aripiprazole may be associated with weight gain in female patients with low-baseline weight. Aripiprazole may have an adverse effect of weight and favorable effects of circulating glucose and lipid on female over male schizophrenia patients. The aripiprazole-induced changes in glucose and lipid may be independent of body fat storage, especially for female schizophrenia patients. Olanzapine may have adverse effects of weight, glucose and lipid profiles on female over male schizophrenic patients. Discussion Our findings fill the gap in knowledge and provide a sex-specific guidance to psychiatrist better tailoring treatment to individual sex-differential characteristics and a key clue to understand the sex-differential mechanism of antipsychotics-induced metabolic dysfunction.
Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Glycémie/effets des médicaments et des substances chimiques , Métabolisme lipidique/effets des médicaments et des substances chimiques , Aripiprazole/effets indésirables , Olanzapine/effets indésirables , Schizophrénie/traitement médicamenteux , Triglycéride/sang , Prise de poids/effets des médicaments et des substances chimiques , Indice de masse corporelle , Facteurs sexuels , Études prospectives , Lipoprotéines HDL/sang , Lipoprotéines LDL/sangRésumé
The prevalence of human papilloma virus (HPV)-16 in patients with cervical cancer,the physical status of HPV-16 in patients with cervical lesions,and the role of HPV-16 integration in cervical carcinogenesis were investigated.HPV genotyping was performed by using PCR approach with the primer GP5+/GP6+ and type-specific primer on biopsy specimens taken operatively from 198 women.Multiple PCR was done to detect physical status of HPV-1 6 in a series of cervical liquid-based cytology samples and biopsy specimens obtained from different cervical lesions with HPV-16 infection,including 112 specimens with cervical cancer,151 specimens with CIN Ⅰ,246 specimens with CIN Ⅱ and 120 specimens with CINⅢ.The results showed that there were 112 cervical cancer samples (56.57％ of total cervical cancer patients) with HPV-16 infection.The frequency of HPV-16 pure integration was 65.18％ (73/112),56.57％ (47/120),23.58％ (58/246) and 7.95％ (12/151) in cervical cancer,CINⅢ,CIN Ⅱ and CIN Ⅰ patients respectively.In situ hybridization was performed on some paraffin-embedded sections of CIN Ⅱ,CINⅢ and cervical cancer to verify the physical status of HPV-16 infection.Significant difference was observed between cervical cancer and CIN Ⅰ,CIN Ⅱ,CINⅢ in the frequency of HPV-16 integration (P＜0.01).It is suggested that HPV-16 is the most prevalent type and is associated with cervical cancer.In the case of HPV-16 infection there are close associations between the severity of cervical lesions and the frequency of HPV-16 integration.The application of testing HPV genotyping and physical status based on detection ofHC- Ⅱ HPV DNA would be in favor of predicting the prognosis of cervical precancerosis and enhancing the screening accuracy of cervical cancer.